Alpha Healthcare Acquisition said its stockholders voted to approve the business combination with Humacyte, a clinical-stage biotechnology platform.
AHAC shareholders approved the business combination proposal with 99.5% votes in favor of the approximately 61.6% of AHAC shares that were voted at the meeting. Neither the press release nor the subsequent 8-K filing mentioned redemptions, if any. Alpha had consistently traded above $10 this month except for a single dip to close at $9.21 on Aug. 19, bouncing back above $10 the next day.
The deal is expected to close tomorrow. Humacyte stock and warrants are expected to begin trading Aug. 27 on the Nasdaq under HUMA and HUMAW.
Humacyte is developing universally implantable bioengineered human tissue at commercial scale. Read more.
